Quantcast

Latest Cytokinetics Incorporated Stories

2011-03-17 21:02:25

Novel mechanistic approach to directly modulating muscle contractility may represent a promising strategy to treat systolic heart failure Cytokinetics, Incorporated (Nasdaq: CYTK) announced today the publication of preclinical research in the March 18, 2011 issue of the journal Science regarding the activation of cardiac myosin by an investigational drug candidate, omecamtiv mecarbil, and the potential therapeutic role that this novel mechanism may play for patients with systolic heart...

2009-05-26 06:48:00

Cytokinetics Receives Exercise Fee of $50 Million Cytokinetics to Host a Conference Call Tuesday, May 26, 2009 at 9 AM ET SOUTH SAN FRANCISCO, Calif. and THOUSAND OAKS, Calif., May 26 /PRNewswire-FirstCall/ -- Cytokinetics Incorporated (Nasdaq: CYTK) and Amgen Inc. (Nasdaq: AMGN) today announced that Amgen has exercised its option to obtain an exclusive license, worldwide (excluding Japan), to Cytokinetics' cardiac contractility program. The license includes CK-1827452, a novel cardiac...

2008-12-23 15:05:00

- GlaxoSmithKline continues to lead development activities for GSK-923295 LONDON, Dec. 23 /PRNewswire-FirstCall/ -- GlaxoSmithKline (GSK) and Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that GSK has informed Cytokinetics that it will not exercise its option to license ispinesib or SB-743921 as provided under the Collaboration and License Agreement entered into by the companies in 2001. All rights to ispinesib and SB-743921, each novel inhibitors of kinesin spindle protein...

2008-11-05 18:00:22

Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present corporate updates at two investor conferences in November: Mr. Blum plans to present at Rodman & Renshaw's 10th Annual Healthcare Conference on Wednesday, November 12, 2008 at 9:30 a.m. Eastern Time at The Palace Hotel in New York, New York. He is also scheduled to present at the 17th Annual Credit Suisse Annual Global Healthcare Conference on...

2008-11-03 18:00:20

Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that data relating to a Phase IIa clinical trial for CK-1827452 are scheduled to be presented during a Special Program at the 2008 Scientific Sessions of the American Heart Association which is being held November 8-12, 2008 at the Ernest N. Morial Convention Center in New Orleans, La. These data represent an additional interim analysis of results from Cohorts 1 through 3 and four additional patients from Cohort 4 in an ongoing...

2008-10-30 18:00:29

Cytokinetics, Incorporated (NASDAQ: CYTK), reported revenues from research and development collaborations of $3.1 million for the third quarter of 2008. The net loss for the three months ended September 30, 2008, which included $2.5 million in restructuring charges, was $16.3 million, or $0.33 per share compared to a net loss of $11.3 million, or $0.24 per share for the same period in 2007. As of September 30, 2008, cash, cash equivalents, restricted cash and long-term investments totaled...

2008-10-23 18:00:25

Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that it is scheduled to report third quarter results on Thursday, October 30, 2008 at 4:00 p.m. Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 p.m. Eastern Time to discuss operational and financial results and the company's outlook for the future. The conference call will be simultaneously webcast and can be accessed in the Investor Relations section of Cytokinetics'...

2008-10-23 09:00:10

Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that three posters containing data on GSK-923295, an inhibitor of centromere-associated protein E (CENP-E), and one poster containing data on SB-743921, an inhibitor of kinesin spindle protein (KSP), were presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics held at the Geneva Palexpo, Geneva, Switzerland. Three posters presented today contain preclinical or clinical data relating to GSK-923295,...

2008-10-20 09:00:42

Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that data relating to a Phase IIa clinical trial for CK-1827452 were presented during a Special Program at the 12th Annual Scientific Meeting of the Japanese Heart Failure Society, which was held October 16-18, 2008 at the Hotel Pacific Tokyo in Tokyo, Japan. These data represent an interim analysis of results in an ongoing Phase IIa clinical trial evaluating CK-1827452 in stable heart failure patients. CK-1827452 is a novel cardiac...


Word of the Day
tesla
  • The unit of magnetic flux density in the International System of Units, equal to the magnitude of the magnetic field vector necessary to produce a force of one newton on a charge of one coulomb moving perpendicular to the direction of the magnetic field vector with a velocity of one meter per second. It is equivalent to one weber per square meter.
This word is named for Nikola Tesla, the inventor, engineer, and futurist.